Journal of Neuro-Oncology

, Volume 65, Issue 3, pp 261–267 | Cite as

Clinical Gene Therapy for Brain Tumors. Liposomal Delivery of Anticancer Molecule to Glioma

  • Jun Yoshida
  • Masaaki Mizuno
Article

Abstract

Liposomes are one of the most promising delivery systems for genes, proteins, and other biological molecules and they are expected to become a new therapeutic tool for the treatment of brain tumors, especially malignant gliomas. Until now, transfer of anticancer molecules using liposomes has been studied by a lot of investigators and it has been found to induce regression of experimental gliomas, resulting in establishing some original and effective therapies. Gene therapy using cationic liposomes is also one of them. Here we introduce the advanced medicine for brain tumors using liposomes containing some anticancer molecules (for example, gene, antibody, antisense, or magnetite), based on our basic and clinical research.

brain tumor gene therapy interferon liposome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bethune CR, Geyer RJ, Spence AM, Ho RJ: Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats. Cancer Res 61: 3669-3674, 2001Google Scholar
  2. 2.
    Kito A, Yoshida J, Kageyama N, Kojima N, Yagi K: Liposomes coupled with monoclonal antibodies against glioma-associated antigen for targeting chemotherapy of glioma. J Neurosurg 71: 382-387, 1989Google Scholar
  3. 3.
    Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM:Receptormediated delivery of an antisense gene to human brain cancer cells. J Gene Med 4: 183-184, 2002Google Scholar
  4. 4.
    Koukourakis MI, Koukourakis S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N: High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastoma and in metastaic brain tumours. Br J Cancer 86: 659-661, 2002Google Scholar
  5. 5.
    Cerletti A, Drewe J, Fricker G, Eberie AN, Huwyler J: Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8: 435-446, 2000Google Scholar
  6. 6.
    Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JR, Ringold GM, Danielson M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7414, 1987Google Scholar
  7. 7.
    Felgner RL, Ringold GM: Cationic liposome-mediated transfection. Nature 337: 387-388, 1989Google Scholar
  8. 8.
    Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizaka T, Yagi K: Growth inhibition of glioma cells transfected with the human β-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50: 7826-7829, 1990Google Scholar
  9. 9.
    Mizuno M, Yoshida J, Sugita K, Yagi K: Growth inhibition of glioma cells of different cell lines by human interferon-? produced in the cells transfected with its gene by means of liposomes. J Clin Biochem Nutr 9: 73-77, 1990Google Scholar
  10. 10.
    Yoshida J, Mizuno M, Yagi K: Secretion of human ?-interferon into the cystic fliud of glioma transfected with the interferon gene. J Clin Biochem Nutr 11: 123-128, 1991Google Scholar
  11. 11.
    Yoshida J, Mizuno M, Yagi K: Antitumor effect of endogenous human ?-interferon on malignant glioma and augmentation of the effect by tumor necrosis factor-±. J Clin Biochem Nutr 12: 153-160, 1992Google Scholar
  12. 12.
    Mizuno M, Yoshida J, Oyama H, Sugita K: Growth inhibition of glioma cells by liposome-mediated cell tansfection with tumor necrosis factor-α gene. Its enhancement by prior ?-interferon treatment. Neurologia medico-chirurgica (Tokyo) 32: 873-876, 1992Google Scholar
  13. 13.
    Yoshida J, Mizuno M, Yagi K: Cytotoxicity of human β-interferon produced human glioma cells transfected with its gene by means of liposomes. Biochemistry International 28: 1055-1061, 1992Google Scholar
  14. 14.
    Yagi K, Noda H, Kurono M, Ohishi N: Efficient gene transfer with less than cytotoxicity by means of cationic multilamellar liposomes. Biochem Biophys Res Commun 196: 1042-1048, 1993Google Scholar
  15. 15.
    Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756, 1989Google Scholar
  16. 16.
    Schulze-Osthoff K, Krammer PH, Droge W: Divergent signaling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 13: 4587-4596, 1994Google Scholar
  17. 17.
    Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993Google Scholar
  18. 18.
    Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas gene transfer for human malignant glioma. Cancer Res 55: 2936-2944, 1995Google Scholar
  19. 19.
    Ohta S, Mizuno M, Takaoka T, Yoshida J: Augmentation of anti-Fas antibody-mediated apoptosis on human glioma cells by liposomes associated with the antibody. J Neuro-Oncol 35: 7-11, 1997Google Scholar
  20. 20.
    Sugawa N, Ueda S, Nakagawa Y, Nishino H, Nosaka K, Iwashima A, Kurimoto M: An antisense EGFR oligonucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neuro-Oncology 39: 237-244, 1998Google Scholar
  21. 21.
    Wiesenhofer B, Weis C, Humpel C: Glial cell line-derived neurotrophic factor (GDNF) is a proliferation factor for rat C6 glioma cells: evidence from antisense experiments. Antisense Nucleic Acid Drug Dev 10: 311-321, 2000Google Scholar
  22. 22.
    Shinkai M, Ueda K, Ohtsu S, Honda H, Kohri K, Kobayashi T: Effect of fuctional magnetic particles on radiofrequency capacitive heating: an in vivo study. Jpn J Cancer Res 93: 103-108, 2002Google Scholar
  23. 23.
    Ito A, Shinkai M, Honda H, Kobayashi T: Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 9: 649-654, 2001Google Scholar
  24. 24.
    Zerrouqi A, Rixe O, Ghoumari AM, Yarovoi SV, Mouawad R, Khayat D, Soubrane C: Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir. Cancer Gene Ther 3: 385-392, 1996Google Scholar
  25. 25.
    Voges J, Weber F, Reszka R, Sturm V, Jacobs A, Heiss WD, Wiestler O, Kapp JF: Clinical protocol. Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme. Hum Gene Ther 13: 675-685, 2002Google Scholar
  26. 26.
    Von Eckardstein KL, Patt S, Zhu J, Cervos-Navarro J, Reszka R: Short-term neuropathological aspects of in vivo suicide gene transfer to the F98 rat glioblastoma using liposomal and viral vectors. Histol Histopathol 16: 735-744, 2001Google Scholar
  27. 27.
    Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Lowenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implication for clinical trials. Nat Med 5: 1256-1263, 1999Google Scholar
  28. 28.
    Mabuchi E, Shimizu K, Miyao Y, Kaneda Y, Kishima H, Tamura M, Ikenaka K, Hayakawa T: Gene delivery by HVJ-liposome in the experimental gene therapy of murine glioma. Gene Ther 4: 768-772, 1997.Google Scholar
  29. 29.
    Mizuno M, Yoshida J: Effect of human interferon-b gene transfer upon human glioma transplanted into nude mouse brain involves induced natural killer cells. Cancer Immunol Immunother 47: 227-232, 1998Google Scholar
  30. 30.
    Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon-b gene transfer against intracerebral glioma in mouse. Gene Therapy 6: 1626-1633, 1999Google Scholar
  31. 31.
    Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J: IFN-b gene therapy induces systemic antitumor immunity against malignant glioma. J Neuro-Oncology 47: 117-124, 2000Google Scholar
  32. 32.
    Berns KI, Bohensky RA: Adeno-associated virus: an update. Adv Virus Res 32: 243-306, 1987Google Scholar
  33. 33.
    Srivastava A, Lusby EW, Berns KI: Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 45: 555-564, 1983Google Scholar
  34. 34.
    Atchinson RW, Castro BC, Hammond WM: Adenoassociated defective particles. Science 149: 754-756, 1965Google Scholar
  35. 35.
    Buller RM, Janik JE, Sebring ED, Rose JA: Herpes simplex virus types 1 and 2 completely help adeno-associated virus replication. J Virol 40: 241-247, 1981Google Scholar
  36. 36.
    Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA: Targeted integration of adenoassociated virus (AAV) into human chromosome 19.EMBO J 10: 3941-3950, 1991Google Scholar
  37. 37.
    Linden RM, Ward P, Giraud C, Winocour E, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93: 11288-11294, 1996Google Scholar
  38. 38.
    Mizuno M, Yoshida J: Improvement of transduction effi-ciency of recombinant adeno-associated virus vector by entrapment in multilamellar liposomes. Jpn J Cancer Res 89: 352-354, 1998Google Scholar
  39. 39.
    Natsume A, Mizuno M, Ryuke Y, Yoshida J: Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. Jpn J Cancer Res 91: 363-367, 2000Google Scholar
  40. 40.
    Mizuno M, Ryuke Y, Yoshida J: Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse subcutaneous glioma model. Cancer Gene Ther 9: 825-829, 2002Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Jun Yoshida
    • 1
  • Masaaki Mizuno
    • 2
  1. 1.Department of NeurosurgeryNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Molecular NeurosurgeryNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations